At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 65 enrolled
Drug / intervention
Denosumb +1 moredrug
Likely dose
Denosumb 1 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women: a Randomized, Double-blind, Placebo-controlled Study
In Brief
A Phase 4 clinical trial evaluating Denosumb and Placebo (for denosumab) for Hip Osteoarthritis. Completed, enrolled 65 participants across 1 site.
Detailed Summary
This randomized clinical trial will evaluate the efficacy of an antiresorptive osteoporosis drug (denosumab) in prevention of periprosthetic bone loss and in promotion of implant osseointegration (bone bonding) in postmenopausal women after total hip replacement. The investigators assume that denosumab prevents periprosthetic bone loss and enhances bone bonding of the hip stem in postmenopausal women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHip Osteoarthritis
CountriesFinland
CollaboratorsAmgen
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartDec 2013
Primary CompletionFeb 2017
Study CompletionDec 2017
TodayJul 2026
First PostedAug 20, 2013
Enrollment StartDec 1, 2013
Primary CompletionFeb 4, 2017
Study CompletionDec 31, 2017
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 12.9 years ago
Interventions
Denosumbdrug
Prefilled syringe of 1 mL denosumab solution
Placebo (for denosumab)drug